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ABSTRACT 
 
Infection with the hepatitis B virus (HBV) is still a major global health problem with an 
estimated 6% of the world’s population chronically infected with the virus. Chronic 
infection with HBV subgenotype A1, which is hyperendemic to southern Africa, is 
associated with a particularly high incidence of liver cancer and cirrhosis. 
Understanding HBV replication and developing effective HBV treatment to prevent 
liver cancer remain important medical priorities. Although there is a preventative 
vaccine for HBV, efficacy of currently available treatment of established infection is 
limited. Exploiting the RNA interference (RNAi) pathway through the use of small 
interfering (siRNA) and short hairpin RNA (shRNA) is an attractive new approach for 
the development gene therapies against HBV infection. Our laboratory has designed 
and demonstrated the efficacy both in vitro and in vivo of several shRNAs designed to 
target the X open reading frame (ORF) of HBV. Thus, the objective of this study was 
to construct a replication competent plasmid vector of the A1 subgenotype, a reporter 
plasmid vector of HBV and to assess the efficacy of RNAi effecters against these 
vectors both in vitro and in vivo. The first HBV replication competent vector, pCR-
HBVA1 1.3x, containing the sequence of an HBV subgenotype A1 isolate, was 
successfully constructed by generating a greater than genome length sequence of 
HBV, that starts just upstream of endogenous HBV basic core promoter (BCP) and 
ends just downstream of the unique HBV polyadenylation (pA) site. Human hepatoma 
(Huh7) cells transfected with this plasmid secreted HBV surface antigen (HBsAg) into 
Abstract  viii 
culture supernatants. In the murine hydrodynamic injection model of HBV replication, 
serum HBsAg, hepatitis B e antigen (HBeAg) and viral particle levels as well as 
relative surface and core mRNA levels were shown to be significantly elevated as 
compared to mock-injected mice. The second HBV vector, pCH-FLuc, was 
successfully generated by replacing the surface ORF with the sequence encoding 
Firefly Luciferase. The ability of pCH-FLuc to express Firefly Luciferase was 
demonstrated in a liver cell line (Huh7 cells). Co-transfection of the reporter plasmid, 
pCH-FLuc, with shRNAs targeted to HBV caused a significant reduction in Luciferase 
expression. Co-transfection/injection of the pCR-HBVa1 1.3x with shRNAs caused 
significant inhibition in the level of viral antigens (HBsAg, HBeAg and hepatitis B core 
antigen (HBcAg) as well as relative surface and core mRNA levels. This was 
observed both in vitro and in vivo. Our results demonstrate the potential this model 
allows for the study of HBV replication as well as the assessment of potential 
therapeutic strategies in a regionally significant subgenotype of HBV.  
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CHAPTER 1 
1    INTRODUCTION 
1.1 The hepatitis B virus 
1.1.1 Hepatitis B virus biology 
 
The hepatitis B virus (HBV) causes both acute and chronic infection of the liver (1). 
There are approximately 350 million chronic carriers of HBV (2). Chronic HBV 
infection is endemic in several areas including sub-Saharan Africa, east and South-
East Asia, and the western Pacific islands where between 8-15% of the population 
are chronic carriers (3). The clinical course of HBV infection is variable and may be 
influenced by individual viral and host variants (4). For example, chronic infection with 
HBV subgenotype A1, which is hyperendemic to sub-Saharan Africa, is associated 
with a particularly high risk of hepatocellular carcinoma (5). An effective vaccine has 
been available for nearly 20 years and vaccination is included as part of Expanded 
Programme of Immunization (EPI) in developing countries including areas of endemic 
infection. It’s effectiveness in preventing blood borne transmission from a mother to 
her newborn child is about 90% (6). However, vaccination does not treat established 
infections. Licensed treatments which include interferon-α, lamivudine and adefovir 
dipivoxil are the only available treatments for chronic HBV infection (7). These drugs 
have only 20 to 30% efficacy in patients with chronic HBV infection (8). 
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Understanding HBV replication and pathogenesis for the development of effective 
HBV treatment to prevent liver cancer therefore remain important medical priorities. 
Exploiting the RNA interference (RNAi) pathway has shown exciting promise for the 
development of novel anti HBV therapy (9).  
 
1.1.2 Life cycle of HBV  
 
HBV is a small enveloped hepatotropic DNA virus which replicates essentially in 
parenchymal cells of the liver (10). The HBV life cycles involves attachment of 
infectious virions to cellular receptor(s), uncoating and releasing nucleocapsids that 
migrate to the cell nucleus (Figure 1.1). Early events in the viral life cycle are poorly 
understood due to the lack of knowledge about the mode of receptor mediated 
infection of the host hepatocytes and absence of cell lines and small animals that are 
susceptible to HBV infection. Although the mechanisms by which HBV enters the cell 
is poorly understood, it appears that receptor components are necessary for HBV-
mediated infection of hepatocytes (10). After the virus has entered into hepatocytes it 
is uncoated and releases its nucleocapsid which migrates to the cell nucleus, where 
the partially double-stranded viral genome is converted into covalently closed circular 
DNA (cccDNA), which is the template for the transcription of four viral (the 
pregenomic RNA, the pre-S (L) mRNA, the S mRNA and the X mRNA). Translation 
occurs following transcript export to the cytoplasm. 
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Figure 1.1: Schematic representation of the HBV life cycle. The virus is recognised by cell 
and binds to cellular receptor(s), uncoating and releasing nucleocapsids that migrate to the 
cell nucleus, where the partially dsDNA genome is converted into cccDNA. The cccDNA then 
serves as the template for transcription of functional genome and subgenomic mRNAs. 
Pregenome RNA is translated into polymerase. The dsDNA HBV can re-enter the nucleus to 
form more cccDNA or mature virus can assembled with envelope in the ER membranes and 
virion are released  from cells (1-2). 
 
HBV protein  
HBV mRNA  
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The pregenomic RNA (pgRNA) serves as the mRNA for the synthesis of core protein 
and reverse transcriptase. HBV replicates its genome by reverse transcription of the 
pgRNA. The reverse transcriptase binds to the 5’ end of its own mRNA template, and 
the complex is packaged into nucleocapsids, where viral DNA synthesis occurs 
through reverse transcription. After partially double stranded DNA has been 
produced, the mature nucleocapsids containing the HBV DNA genome are 
assembled with envelope polypeptides in the endoplasmic reticulum membranes, and 
the virions are released from the cell  (1, 2, 10). 
 
1.1.3 The viral genome and proteins 
  
The HBV genome is the smallest of all animal viral genomes being 3.2 kilobase (Kb) 
in size (10)  (Figure 1.2).  It is composed of relaxed circular, partially double stranded 
DNA (rcDNA) (2). The long (or minus) strand covers the complete viral genome (3.2 
kb) and has the viral polymerase priming protein (reverse transcriptase) bound to its 
5’ terminus. The short (or plus) strand is incomplete, varies in length and maintains 
the genome circularity by a cohesive overlap across the 5’ and 3’ ends of the minus 
strand.  The HBV genome has four primary open reading frames (ORFs) which 
partially overlap each other and encode the surface, core, polymerase and X proteins. 
Transcription from the ORFs is initiated by 4 promoters: the Nucleocapsid/Core 
promoter, X promoter and two Surface promoters and two enhancers (Enhancer I and 
Enhancer II). In addition, cis-acting negative regulatory elements also function in the 
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Figure 1.2: Schematic representation of the HBV genome (46). Coordinates of the genome 
are given relative to the single EcoR I restriction site. The partially double stranded HBV DNA 
genome comprises + and – strands with cohesive complementary 5’ ends. The cis- elements 
that regulate HBV transcription are represented by the circular and rectangular symbols.  
Arrows immediately surrounding the HBV genome indicate the four open reading frames. 
Four arrows, which give the 5’ to 3’ polarity, indicate the HBV transcripts.  
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regulation of viral genes. Transcription from the four ORFs results in formation of the 
4 transcripts of 3.5 2.4, 2.1 and 0.9 kb. The single polyadenylation signal terminates 
transcription at a common 3’ end for all transcripts. The 3.5 kb pgRNA serves as 
template for the core and polymerase proteins. The 2.4 kb RNA encodes the large 
surface antigen; the 2.1 kb transcript encodes the middle and small surface antigens 
and the 0.9 mRNA codes for hepatitis B virus X protein (HBx). The three viral surface 
antigens (HBsAg) are thought to play key roles in the binding of the virus to the host-
cell receptors, in the assembly of the virion and its release from cells. The preC/C 
(precore/core) region encodes the viral proteins, known as HBV core antigen (HBcAg) 
and HBV e antigen (HBeAg). The HBcAg forms the nucleocapsid; whereas HBeAg is 
dispensable for infection in vivo. The P region is specific for the viral polymerase, 
DNA synthesis and RNA encapsidation. The X ORF encodes the viral X protein which 
is required for infection and replication in liver cells in vivo  (11-13). 
 
The core promoter consists of the basic core promoter (BCP) and an upstream 
regulatory sequence. The BCP is defined as the region which has cis-acting elements 
that direct the precise initiation of both the preC and pregenomic RNAs.  The 
sequence immediately 5’ of the BCP is referred to as the core upstream regulatory 
sequence (CURS). The CURS region contains several domains, designated boxes α, 
β, δ and γ. Box α and box β form part of the bipartite structure of the enhancer II 
element. Several sequence motifs have been shown to interact with ubiquitous and 
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liver specific transcription factors and are located within the BCP and its upstream 
regulatory region (12, 13). 
 
1.1.4 Genotypes and subgenotypes 
Genetic analysis of full length HBV genomes has led to the virus being classified into 
eight genotypes (A to H)  (4).  These genotypes are distinguished by intergenotypic 
differences of more than 8% in the entire genome, which consists of approximately 
3200 base pairs, or at the level of the surface gene by a difference of greater than 
4%. All eight genotypes have different geographic distributions, virological 
characteristics, clinical manifestations and response to antiviral therapies  (14, 15).   
 
The dominant genotype in South Africa is genotype A, which consists of two 
subgenotypes A1 and A2. Subgenotype A1 predominates over subgenotype A2 (16). 
Subgenotype A1 has unique features that are likely to contribute to mutation, disease 
progression and response to antiviral therapy. This subgenotype is hyperendemic to 
southern Africa and is associated with a particularly high incidence of liver cancer and 
cirrhosis (5). Subgenotype A1 has distinctive sequence characteristics within its open 
reading frames that may affect both replication of the virus and the expression of its 
proteins. It is believed that these sequence alterations might account for the 
significantly higher risk of developing hepatocellular cancer (HCC). Because of 
greater nucleotide divergence and endemic infection compared to other genotypes, 
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subgenotype A1 is believed to have a very long natural history within the South 
African black population (16, 17). The unique features of HBV subgenotype A1 and in 
particular the high risk of developing HCC associated with this subgenotype make, 
the understanding of  HBV replication and development of effective HBV treatment 
remain important medical priorities. 
 
1.2 Models of HBV replication 
 
HBV has host- and cell-specific requirements that have made development of cell 
culture systems difficult. Furthermore, effects in cell culture cannot be used reliably to 
predict effects in animals and especially in man. A major way to overcome this 
obstacle to the research is to generate an animal models of HBV replication to 
investigate further the viral life cycle, the development of liver disease (18) and 
antiviral drug efficacy (19). 
 
1.2.1 In vitro model of HBV replication 
 
Passman and colleagues (20) have generated a reporter plasmid of HBV expressing 
enhanced green fluorescent protein (EGFP) as a marker of HBV replication by 
replacing the preS2/S ORF with DNA encoding EGFP. Transfection of cultured cells 
with this reporter plasmid was able to express EGFP instead of HBsAg. In addition, 
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deletion of preS2/S also disrupted the polymerase ORF. The highly conserved HBx 
region which overlaps all viral ORFs was not disrupted. 
 
The two major cell culture models of HBV are primary human hepatocytes and 
hepatoma-derived cell lines. Primary human hepatocytes for infection studies have 
the advantage that they retain important cellular characteristics of differentiated 
hepatocytes allowing natural penetration (i.e. infection), and full replication of HBV 
(18).  However, difficulties arise with this system because within several days they 
lose the capability of supporting HBV replication and culture supernatants from 
infected cells do not always give similar results (21).  In addition, infection of these 
cells with HBV has poor viral replication and low viral yields. Although there are some 
difficulties with this model of HBV infection, it has demonstrated infectivity by the virus 
and may be useful for studying early stages of the viral life cycle (18). 
 
Hepatoma-derived cell lines (e.g HepG 2.2.15) have been generated by the 
integration viral cccDNA under the control of constitutive or inducible promoters. The 
advantages of these cell lines are that integration of the complete HBV genome, 
allows for the expression of HBV RNAs, viral proteins and secretion of virus-like 
particles (22). The disadvantage of this cell line is that it cannot be used to study 
HBV-host cell infection processes such as viral attachment, penetration, and 
uncoating  (21).  
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1.2.2 In vivo models of HBV replication 
 
The lack of convenient animal models of HBV infection has stymied the progress of 
HBV research. Chimpanzees are the only animals fully permissive and well tested for 
HBV infection (23). Studies performed in chimpanzees played a critical role in the 
discovery of HBV and continue to play an essential role in defining the natural history 
of this important human pathogen (23). The discovery of related hepadnaviruses such 
as woodchuck hepatitis virus (WHV), ground squirrels hepatitis virus (GSHV), Arctic 
Squirrel hepatitis virus (ASHV) and duck hepatitis B virus (DHBV) offers opportunities 
for in vivo studies in various animals with naturally occurring hepadnaviruses.  
Recently HBV research has shown progress with the development of various mouse 
strains carrying HBV transgenes (24). HBV replicating mouse models offer the 
opportunity to investigate some of the pathogenic mechanisms responsible for HBV 
associated liver disease, as well as testing specific viral genes for their potential 
oncogenic function in vivo (25). 
 
1.2.2.1 The chimpanzee model 
 
A chimpanzee model of HBV infection is associated with development of acute liver 
infection (26). Although these animals do not develop chronic liver infection, they are 
the only primates known to develop a cellular immune response similar to that 
observed in humans acutely infected with HBV (27). Like humans, when 
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chimpanzees are immunized with HBsAg, they develop high titers of antibodies to 
HBsAg. Chimpanzees have played an important role in investigating the mechanism 
of viral persistence (28) and the development of safe vaccines (29). Due to the limited 
availability, ethical constraints, the large size of the animals, high cost and lack of 
chronic disease of chimpanzees, alternative animal models would be desirable. 
 
1.2.2.2 Surrogate animal models 
 
 
Several non primate HBV-related hepadnaviridae have been identified and studied in 
their natural hosts. Summer and colleagues (30) were first to discover non primate 
hepadnaviruses called WHV, which infects only Eastern woodchucks (Marmota 
monax) in the northeastern part of the USA.  WHV was found to be closely related to 
HBV in its structure, genetic organization and mechanism of replication. Natural 
infection of this animals model is associated with chronic liver disease and HCC (31). 
Other viruses that have similar properties to WHV include GSHV (32), ASHV (33) as 
well as viruses infecting ground squirrels, tree squirrels, and three avian species (34). 
Mammalian hepadnaviruses (in particular WHV) rather than the avian 
hepadnaviruses are the more often used animal models of HBV infection due to 
similarity with HBV in terms of genomic organization and effects of persistent infection 
(23). WHV models have contributed significantly to the understanding of viral 
replication, chronic infection, and hepatic carcinogenicity of hepadnaviruses.  WHV 
models are not ideal models of HBV infection for various reasons, e.g. these viruses 
are genetically divergent from HBV, woodchucks are difficult to breed and there is a 
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lack of immunological reagents to study lymphocyte subsets. Although these animals 
are usefully to establish proof of principle, immunotherapeutic agents against WHV 
will not be effective against HBV, and vaccines against HBV cannot be tested in 
woodchucks. Furthermore, these animals do not develop cirrhosis (18). 
                                                                                                                                                                                                                                       
 
1.2.2.3 Rodent models of HBV replication 
 
 
Despite the availability of permissive animal models (e.g. Chimpanzees) and a good 
model of antiviral therapy and chronic carriers (e.g. Woodchuck model) there is need 
to develop a model of HBV infection that permits researchers to study viral replication, 
gene expression, and immunopathogenesis (35). Recent studies show the 
development of two groups of HBV-replicating mouse models (i.e. HBV transgenic 
mice and hydrodynamically injected mice) with the potential to bridge this gap in HBV 
studies (35).  
 
Transgenic mouse model: Transgenic mice are manipulated by insertion of a gene, 
which is subsequently expressed in every host cell. HBV-transgenic mice have been 
generated expressing HBsAg, preS and X antigens (35).  This animal model provides 
a way to study the function of viral proteins and replication of HBV. Although 
transgenic mice support viral replication and have high levels of HBsAg in circulation, 
HBV is not directly cytopathic (35). In one of the transgenic mouse studies, 
researchers demonstrated that high levels of  HBx in the liver led to the development  
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of HCC (25) and that the X protein impairs the function of p53 (37). Another study 
with transgenic HBV mice indicated that cytotoxic T-lymphocytes (CTLs) may clear 
HBV by non-cytolytic mechanisms via cytokines (38).        
 
Hydrodynamic injection model: During hydrodynamic tail vein injection, a large 
volume of DNA-containing saline is injected via the tail vein of mice and causes 
widening of hepatic sinusoidal fenestrations and creating pores in the plasma 
membrane of hepatocytes (39), thereby enabling the efficient entry of DNA into cells 
(40). Yang and Colleagues (36) demonstrated that the hydrodynamic injection of a 
HBV replication-competent plasmid lead to gene expression and viral replication in 
mice. In the case of the hydrodynamic injection model of HBV, after injection of the 
replication-competent plasmid, viral antigens and replicative intermediates are 
synthesized and virus is secreted into blood. Viral antigens are detectable in the liver 
tissues and sera of mice. HBsAg and HBeAg may be measured using Enzyme-Linked 
Immunosorbent Assay (ELISA) and HBcAg by immunohistochemical staining of liver 
sections. Viral antigens disappear from blood as early as 7 days after injection, after 
the appearance of antiviral antibodies. HBV transcripts and replication intermediates 
also disappear from liver by day 15, after the appearance of antiviral CD8+ T cells. It 
is also thought that this method may be valuable for the characterisation of newly 
discovered viruses as long as they have the potential to replicate in the liver. In the 
case of HBV, this methodology may be useful in the study of generation of HBV 
variants, new models systems to evaluate anti HBV drugs (36). 
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Although infectious virus can be produced from HBV transgenic mice or mice 
hydrodynamically injected, a limitation of the model is that mouse hepatocytes are not 
permissive for HBV infection. Therefore, the still unknown early steps in viral infection, 
such as receptor recognition and mechanism of entry, cannot be addressed in these 
systems (23).  
 
1.3 Treatment of HBV Infection 
 
Despite the availability of an effective vaccine against HBV, the prevalence of chronic 
infection has not significantly decreased (8). Twenty-five percent of patients 
chronically infected with HBV are at risk of developing cirrhosis and primary (41). The 
development of potential antiviral treatment aims to prevent such an undesirable 
outcome. Currently HBV therapy consists of treatment with interferon alpha (IFN-α), 
an immunomodulator, the nucleoside analogue lamivudine and the nucleotide 
analogue adefovir dipivoxil. The standard treatment with these drugs results in a loss 
of HBeAg with or without seroconversion to anti-HBe, normalisation of serum 
transaminase levels, loss of HBV DNA and improvement in liver histology (42). IFN-α 
was approved by the United States of America Food and Drug Administration (FDA) 
for the treatment of chronic HBV infection in 1992 (43). Although, IFN-α is licensed as 
an antiviral agent for treatment of chronic HBV infection its use has numerous 
disadvantages, e.g. expense, poorly toleration (15) and association with several 
undesirable side effects including: fever, myalgias and depression (44). Also, IFN-α is 
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only effective in carriers with actively replicating virus (i.e. HBeAg positive carriers) 
(45). Nucleoside analogues (such as lamivudine) are chemically synthesized 
molecules that are structurally similar to naturally occurring nucleosides.  Lamivudine 
was approved by the FDA in 1998 for the treatment of chronic HBV infection. Since 
lamivudine structurally mimics natural nucleosides it can be incorporated into newly 
reverse transcribed HBV DNA causing chain termination thereby inhibiting viral 
replication (42). Lamivudine has been shown to be more effective in HBeAg-negative 
carriers than HBeAg-positive carriers during 12 months treatment (46). The 
emergence of drug resistant strains of HBV against lamivudine indicates a major 
drawback of the use of this drug. Resistant HBV strains harbor point mutations in the 
HBV polymerase gene, predominantly in the well conserved YMDD (Tyrosine-
methionine-aspartate-Aspartate) motif, such that the methionine (M) at position 552 is 
changed either to valine (YVDD) or isoleucine (YIDD) (47).  Adefovir dipivoxil (a 
nucleotide analogue) was approved by the FDA in 2002 for the treatment of chronic 
HBV infection. However, adefovir dipivoxil acts as a stimulant for natural killer cell 
activity and induces endogenous interferon production (42).  
 
Only 30 to 40 percent of HBV patients respond to treatment with INF-α, lamivudine, 
and adefovir dipivoxil (43). Therefore, there is an urgent need to develop novel 
antiviral therapy for treating chronic HBV infection. Currently, molecular approaches, 
such as the use of RNA interference (RNAi) have become a major focus of 
developing new therapeutic strategies against HBV (48). RNAi is a gene silencing 
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mechanism conserved in all eukaryotes, in which double-stranded RNAs suppress 
the expression of a cognate gene inducing degradation of mRNAs or blocking mRNA 
translation  (49-51). 
                                                                                                                                 
1.4 RNA interference  
 
RNAi is a novel regulatory mechanism that limits gene expression by mediating 
sequence-specific degradation or translational repression of mRNA 
(posttranscriptional gene silencing or PTGS) or by suppressing transcription 
(transcriptional gene silencing or TGS) (50). 
 
 RNAi was originally discovered in 1998 when Fire and colleagues (52) found that the 
injection of dsRNA into the nematode worm Caenorhabditis elegans led to efficient 
sequence-specific gene silencing. RNAi has been observed in nematodes, plants, 
fungi, vertebrates and mammals and appears to be present in almost all eukaryotic 
organisms. 
 
1.4.1 The RNAi pathway 
 
Exploiting the RNAi pathway has shown exciting promise for the development of 
novel antiviral therapy. Naturally, the mechanism involves processing of larger 
dsRNAs to ultimately form RNA duplexes (small interfering RNAs or siRNAs) that are 
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21-22 nucleotides (nt) in length with symmetric 2-3 nt 3’ overhangs and 5’-phosphate 
and 3’-hydroxyl groups (Figure 1.3) (53). Dicer, which belongs to a family of RNase III 
enzymes, first cleaves long dsRNAs to produce siRNAs (54). The second step 
involves incorporation of siRNAs into the multiprotein RNA-inducible silencing 
complex (RISC). The duplex siRNA is unwound, leaving the antisense strand to guide 
RISC to its homologous target mRNA for endonucleolytic cleavage (55). Finally, the 
targeted mRNA is cleaved at a single site in the centre of duplex region between the 
guide siRNA and the targeted mRNA, approximately 10 nt from the 5’ end of the 
siRNA (56).   
 
Mutations in genes encoding RNA-dependent RNA polymerases (RdRP) have been 
shown to be deleterious highlighting the role these genes play in the spread of RNAi 
throughout plants and C. elegans as well as between generations in C. elegans.  The 
mechanism has been elucidated (57).  Using a siRNA as a primer and its target as 
the template, the RdRP generates dsRNA which is recognised by Dicer and cleaved 
to form secondary siRNAs (or new siRNAs). The new siRNAs may be incorporated 
into RISC to function as guides and mediate gene silencing by mRNA degradation or 
re-enter the so-called random degradative PCR pathway (58).  
 
Recent studies revealed that the natural RNAi pathway employs endogenously 
encoded small RNAs (microRNAs or miRNAs) to regulate gene expression (59). 
miRNAs are small RNAs processed from double stranded hairpin structures that are 
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encoded in the genome. miRNAs have been found to be abundant in plants, humans, 
Drosophila melanogaster and C. elegans, and are known to be involved in numerous 
aspects of gene expression (60, 61).  Like siRNAs, miRNAs may mediate gene 
suppression by mRNA degradation when they are completely complementary to their 
target site. However, miRNAs are usually only partially complementary to sites within 
the 3’ untranslated region (UTR) of the target mRNA, resulting in repression of 
translation and inhibition of protein synthesis (62). siRNAs that are designed to be 
partially complementary to their target sites have also been shown to inhibit gene 
expression by translational suppression.  
 
 
1.4.2 Delivery of RNAi-inducing sequences 
 
Inhibition of gene expression using the RNAi pathway is rapidly becoming the method 
of choice for studying gene function in human hepatoma cell line. However, 
successful knockdown of the target gene requires efficient delivery of siRNAs. 
Several technologies have been developed that enable effective delivery of siRNAs to 
both cells in culture and mouse models of HBV replication (63).  
 
Delivery of siRNA or short hairpin RNA (shRNA): A number of transfection reagents 
are being employed for transfection of siRNAs or shRNAs into different cell lines. 
Lipofectamine 2000, liposomes, Oligofectamine and adenoviruses are routinely used  
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Figure 1.3: Schematic representation of the RNAi pathway. Long dsRNA is recognised and processed by Dicer, an RNase 
III enzyme. Synthetic siRNA or endodgenous siRNA are incorporated into RISC and guide the protein complex to target 
mRNA for endonucleolytic cleavage. In plants and worms (C. elegans) the siRNA may act as primers for an RdRP to 
generate nascent dsRNA, which in turn is processed by Dicer to produce secondary siRNA. 
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for siRNA delivery. Lipoplexes and eletroporation has been used successfully to 
introduce siRNAs or shRNAs into cell lines as well as into parasites (48, 64, 65). 
 
siRNA expression vector: An alternative to the use of synthesised siRNAs to induce 
RNAi is to use a vector that expresses siRNAs in the cell. RNA polymerase III (PoI III) 
promoters are commonly used to drive expression of shRNAs that are processed into 
siRNAs. Pol III promoters have the ability to initiate and terminate RNA transcription 
at well defined positions, which allows for the design of precisely defined constructs. 
The Pol III promoters used most often for shRNA expression are the human and 
mouse U6 promoters and the human H1 promoter(63). 
 
1.4.3 RNAi-mediated inhibition of HBV 
 
Several studies of siRNA sequences against HBV have shown significant inhibition of 
gene expression and replication. Efficacy of several different siRNA sequences has 
been assessed in cultured cells as well as murine models of HBV replication (9).  
 
McCaffrey and colleagues (66) assessed the efficacy of the human U6 promoter 
cassettes that encoded shRNA sequences.  The six U6 shRNA cassettes were 
targeted to different HBV ORFs (viz. polymerase, core, surface and HBx ORFs). Of 
these RNAi inducers, shRNA sequences targeted to the surface and polymerase 
ORF demonstrated impressive inhibition of markers of HBV gene expression in vitro 
Chapter 1  21 
and in vivo.  Giladi and colleagues (67) assessed the efficacy of five synthetic siRNAs 
that targeted different sites within the surface ORF of HBV. The siRNA that targeted 
sequence 9-27 nt downstream of the ATG translation start site was found to be most 
effective. HBsAg, HBeAg and the production of HBV RNA from transiently transfected 
HepG2 and HepG2.2.15 as well as in the hydrodynamically injected mice was 
significantly knocked down by this siRNA. In the same study, HBsAg and HBcAg 
expression in liver sections were strongly decreased by this synthetic siRNA. 
Carmona and colleagues (48) assessed the efficacy of a panel of 10 Pol III U6 
promoter-encoded shRNAs that target conserved sequences of the oncogenic HBx 
ORF.  The HBx ORF was chosen as the target region as it is common to all HBV 
transcripts. The two shRNAs which exhibited the highest level of knockdown in vitro 
were shown to be equally effective in vivo. Transfection of shRNAs into Huh7 cells 
markedly diminished the HBsAg secretion in culture supernatants by 80-100%. 
Approximately 100% of HBsAg, HBcAg, and in vivo viral particle equivalents were 
diminished in mice hydrodynamically injected with an HBVreplication-competent 
plasmid and a shRNA cassette. In the same study, significant knockdown was 
observed in transgenic mice of HBV treated with U6 shRNA 5 and U6 shRNA 6 
delivered using recombinant adenoviral vectors. Ying and colleagues (64) assessed 
the effects of three anti HBV 21-bp shRNAs targeted to the HBsAg, HBcAg and 
polymerase ORFs. HBsAg secretion was reduced by 80% in cell culture and 
approximately 90% in vivo.  HBeAg secretion was also significantly inhibited after 
treatment with RNAi effecters. Analysis of HBsAg and HBcAg expression in liver 
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sections also revealed substantial reduction in these proteins in mice treated with 
shRNAs. These shRNAs also showed a significant inhibition in the levels of HBV 
mRNA, as measured by reverse transcriptase polymerase chain reaction (RT-PCR) 
and HBV DNA (as detected by southern blot).  The shRNA targeted to the surface 
region was a more effective inhibitor of HBV antigen secretion in these studies (63).  
 
1.5 Aims  
 
This study is aimed at developing target vectors as a tool for studying gene function, 
and assessing exploitation of the RNAi pathway to inhibit HBV gene expression. 
These will be achieved by: 
 (a).    Constructing a HBV reporter vector. The vector generated should expresses 
Firefly luciferase as a marker of HBV replication in order to allow for accurate 
quantification of HBV viral replication. 
(b).     Constructing a HBV replication-competent plasmid of subgenotype A1. The 
vector should a greater than genome length of HBV subgenotype A1. 
(c).      Assessing the efficacy of RNAi effecters against these vectors both in vitro and 
in vivo. The ability of effecters of RNAi to mediate inhibition of HBV replication 
was to be assessed in the human hepatoma cell line, Huh7 and in a mouse 
model of HBV replication. 
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This study used three U6 shRNA (U6 shRNA 5, U6 shRNA 6 and U6 shRNA 10) 
previously described by Carmona and collogues (48) to target the viral HBx ORF. The 
HBV genome has four primary ORFs which have a common polyadenylation signal 
immediately downstream of the HBx ORF. The HBx ORF is thus common to all 
transcripts and RNAi effecters targeted to the HBx ORF would therefore act against 
all viral transcripts. HBx also plays an important role in the establishment of a 
successful viral infection and replication in vivo. These factors make the HBx ORF an 
ideal therapeutic target. 
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CHAPTER 2 
2     MATERIALS AND METHODS  
2.1 Target vector and reporter plasmid 
2.1.1 Construction of pCH-FLuc 
 
The plasmid pCH-9/3091 (68) contains a greater than genome length sequence of 
HBV DNA cloned downstream of the CMV promoter, allowing the plasmid to simulate 
viral replication when introduced into cells. Replacing the surface ORF with the 
sequence encoding Firefly luciferase would generate a plasmid expressing Firefly 
luciferase as a marker of HBV replication.  
 
The reporter plasmid was generated using a PCR-based approach. The primers used 
(Inqaba Biotech, SA) were designed such that the amplicons generated contained a 
Spe I restriction site upstream and an inframe Xho I restriction site downstream of 
Firefly luciferase.  The Firefly luciferase sequence was amplified by PCR (PCR 
Master Mix; Promega, WI, USA) from pCI-neo-Luc (pCI-neo containing the Firefly 
luciferase sequence) using the primer set in Table 2.1. PCR reaction  conditions were 
as follows: initial denaturation at 95oC for 2 minutes, followed by 30 cycles of 
denaturation at 95oC for 30 seconds, annealing at 55oC for 30 seconds and extension 
at 72oC for 1 minute; a final extension step was carried out at 72oC for 2 minutes. 
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The amplicons were subjected to agarose gel electrophoresis on a 0.8% gel, eluted 
and purified using the MinElute™ Gel Extraction Kit (Qiagen, CA, USA). The purified 
fragments were ligated into the pTZ57R/T cloning vector according to the 
manufacturers’ instructions (Fermentas, WI, USA) (Figure 2.1A). Briefly, the 
fragments were ligated at 22oC overnight in a 30 µl reaction volume containing T4 
DNA ligase and ligase buffer.  Ten microlitres of ligation mix was used to transform 50 
µl of chemically competent Escherichia coli (E. coli) (DH5α, Invitrogen, CA, USA). For 
preparation and transformation of chemically competent E.coli see Appendix 6.1.1. 
The transformed E. coli were plated on Luria Bertani amplicillin-containing agar plates 
(see appendix 6.1.1) and incubated at 37oC overnight. White colonies were selected 
and screened after restriction enzyme digestion with Xho I and Spe I.        
 
To incorporate the DNA sequence encoding Firefly luciferase into pCH-9/3091, pTZ-
FLuc was restricted with Xho I and Spe I (Figure 2.1B). The digested fragments were 
subjected to agarose gel electrophoresis and the desired fragments eluted using the 
MinElute™ Gel Extraction Kit. pCH-9/3091 was digested with Xho I resulting 
linearised product. The linearised pCH-9/3091 was partially digested with Spe I in 
buffer Tango 10x (Fermentas, WI, USA) at 37oC for 30 minutes (Table 2.2). The pCH-
9/3091 backbone lacking the surface ORF was eluted from 0.8% agarose gel using 
standard phenol chloroform purification procedures.  A ligation reaction was set up 
with 3 µg of the Firefly Luciferase fragment together with 1 µg of the pCH-9/3091 
backbone in a 30 µl reaction volume containing T4 DNA ligase (Fermentas, WI, USA) 
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(Figure 2.1). Purified PCR product was quantified spectrophotometrically (Shimadzu 
Corporation, Japan) at 260 nm, A260 of 1.0 = 50 µg/ml DNA. The ligation mixture was 
incubated at 22oC overnight. Chemically competent E. coli (DH5α) were transformed 
with 10 µl of the ligation mix, plated on ampicillin positive Luria Bertani agar plates 
and incubated at 37oC overnight (Appendix 6.1.1).  Clones positive for single unit 
insert (pCH-FLuc) were screened with Xho I and Spe I.        
 
2.1.2 Construction of pCR-HBV A1 1.3x 
 
The plasmid pCR-XL-TOPO-HBV (pCR-HBVA1 1x), kindly provided by Prof. Anna 
Kramvis, Molecular Hepatology Research Unit (MHRU), Department of Medicine, 
University of the Witwatersrand, was generated by cloning the full length genome of a 
subgenotype A1 isolate from a South African HBV chronic carrier.  
 
The target plasmid pCR-HBVA1 1.3x was also generated using a PCR based 
approach (Figure 2.2). The primers (Integrated DNA Technologies, IA, USA) were 
designed such that the amplicons generated contain a  Hind III site upstream and a 
Pci I site downstream of the Basic Core Promoter (BCP),  and an Fsp I site upstream 
and an Apa I site downstream of the  polyadenylation signal (pA) (Table 2.2). The 
sequences encoding the BCP and pA were amplified by PCR from pCR-HBVA1 1x. 
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Figure 2.1 Diagrammatic illustration of cloning strategy for the generation of the HBV plasmid 
expressing Firefly Luciferase (pCH-FLuc) as a marker of HBV replication. (A) Construction of 
pTZ-FLuc, and (B) Construction of the pCH-FLuc reporter plasmid.  
 
pCH-FLuc 
pTZ-FLuc 
B 
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Table 2.1: Oligonucleotide sequences for the generation of Firefly Luciferase 
fragment.  
 
Restriction sites Xho I and Spe I in the forward and reverse primers respectively are underlined 
 
Table 2.2: Serial dilution used to perform partial digest with Spe I from linearised 
pCH-9-3091 product (pCH-9/3091 digested with Xho I). 
____________________________________________________________________ 
           
 
 
Tube 1 Tube 2 Tube 3 Tube 4 
pCH-9/3091 (Xho I)  10µl  10 µl  10 µl  5 µl  
Buffer   Tango 10x     4 µl  2µl   2µl  2µl  
Spe I       1µl  -   -  - 
Sterile H20     5µl  3µl  3µl  3µl 
Total volume    15µl  15µl  15µl  15µl 
____________________________________________________________________ 
 
5µl 5µl 5µl 
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Table 2.3 Oligonucleotide sequence used to amplify BCP and pA fragments from 
pCR-HBVa1 1x. 
 
Restriction sites are underlined. Fsp I and Apa I in forward and reverse pA primers, respectively and 
Hind III and Pci I in the forward and reverse BCP primers, respectively. 
 
PCR reaction conditions were as follows: initial denaturation at 95oC for 2 minutes, 
followed by 30 cycles of denaturation at 95oC for 30 seconds, annealing at 55oC for 
30 seconds and extension at 72oC for 1 minute, final extension step was carried out 
at 72oC for 2 minutes. 
 
The amplicons were subjected to agarose gel electrophoresis and purified using the 
MinElute™ gel Extraction Kit. The purified fragments were ligated into the pTZ57R/T 
cloning vector according to the manufacturer’s instructions (Figure 2.2 A). Ten 
microlitres of ligation mix was used to transform 50 μl of chemically competent E. coli. 
The transformed E. coli were plated on Luria Bertani ampicillin containing agar plates. 
Colonies were selected and screened by restriction enzyme digestion with Hind III 
and Pci I, Fsp I and Apa I for BCP and pA sequences, respectively.  
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The BCP and pA sequences were cloned upstream and downstream of the full length 
subgenotype A1 sequence, respectively to generate the replication competent 
plasmid pCR-HBVA1 1.3x (Figure 2.2 B). The sequence encoding the BCP was 
removed from pTZ-BCP with Hind III and Pci I. Similarly the pA signal was also 
removed from pTZ-pA with Fsp I and Apa I. pCR-HBVa 1x was digested separately; 
first with Hind III an Apa I to yield the pCR-XL-Topo backbone and then with Pci I and 
Fsp I to yield the HBV subgenotype A1 fragment. A Four-way ligation reaction was 
set up with the purified BCP, pA, HBVa1 and pCR-XL-Topo fragments in a 20 μl 
reaction volume containing T4 DNA ligase. The ligation mixture was incubated at 
25oC overnight. Chemically competent bacterial strain (DH5α) were transformed with 
10 μl of the ligation mix, then plated on Kanamycin positive Luria Bertani agar plates 
and incubated at 37oC overnight (Appendix 6.1.1). Clones positive for single unit 
insert (pCR-HBVA1 1.3x) were screened with Hind III and Pci I as well as Fsp I and 
Apa I restriction enzymes. 
 
2.2 Construction of short hairpin RNA expression cassettes 
 
Construction of the short hairpin (shRNA) expression cassettes has been previously 
described (48). Briefly, the sequences of local HBV isolates were aligned with the 
Bioinformatics programme, GeneDoc and the most conserved region of the HBx ORF 
chosen as target sites. shRNA expression cassettes were then designed to target the 
most conserved regions of the HBx ORF. The shRNA were designed with 25 nt stems  
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Figure 2.2 Diagrammatic illustration of cloning strategy for the generation of HBV replication 
competent plasmid (pCR-HBVA1 1.3x) containing a greater than genome length sequence of 
the viral A1 subgenotype. 
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containing G:U wobble bases and loop sequence of miRNA-23. The expression 
cassettes were constructed in accordance with the PCR-based techniques develop 
by Castanotto and colleagues (69). 
 
2.3 DNA extraction  
 
2.3.1 Isolation of plasmid DNA  
 
All plasmids used in this study are listed in Table 2.4. Plasmid DNA was isolated 
using EndoFree® Plasmid Maxi kit (Qaigen, GmbH, Germany). Two hundred and fifty 
milliliters of Luria Bertani medium (Appendix 6.1.1) was inoculated with a single 
colony containing the plasmid of interest and incubated at 37°C with shaking (100 
rpm) overnight. The plasmid DNA was isolated according to the manufacturer’s 
protocol (Appendix 6.1.2). The quality of plasmid DNA was assessed by agarose gel 
electrophoresis (Appendix 6.1.3). The quantity of plasmid DNA was also determined 
spectrophotometrically (Shimadzu Corporation, Japan).   
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2.4 Characterisation of HBV plasmids 
 
2.4.1 Characterisation of HBV vectors in cultured cells 
 
2.4.1.1 Transfections 
 
Human hepatoma cells, Huh7, were maintained in RPMI supplemented with 2.5% 
foetal calf serum (FCS), penicillin (50 IU/ml) and streptomycin (50 µg/ml) (Gibco BRL, 
UK). On the day prior to transfection, 150 000 Huh7 cells (counted using 
haemocytometer) were seeded in wells 1 cm in diameter. To assess the expression 
from pCH-FLuc and pCR-HBVA1 1.3x plasmids, Huh7 cells were transfected with 1.7 
µg of the respective HBV vector. The plasmid DNA was transfected into Huh7 cells as 
per Lipofectamine 2000 (Invitrogen, CA, USA) protocol (Appendix 6.1.4). 
 
2.4.1.2 Assays for markers of HBV replication 
 
Luciferase activity 
 
 
To assess the luciferase activity of pCH-FLuc, Huh7 cells were transfected with 1.7 
µg of pCH-FLuc and 0.2 µg pCMV-GFP (a vector encoding enhanced green 
fluorescent protein). Forty eight hours post-transfection cells were analysed for EGFP 
expression by Confocal Microscopy (Axiovert 100M, Zeiss, Germany) under a FITC 
filter. Lysates were then prepared from transfected cells as per luciferase protocol 
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(Appendix 6.1.5) and then analysed by Dual Luciferase® Reporter Assay System 
(Promega, WI, USA) using the Veritas Microplate luminometer (Appendix 6.1.5). 
 
HBsAg secretion 
 
Forty eight hours post-transfection the medium was collected from cells, to assess the 
replication competency of pCR-HBVA1 1.3x. The cells were transfected with 1.7 µg of 
pCH-9/3091 (control replication competent plasmid), or pCR-HBVA1 1x (HBV plasmid 
that is not replication competent) or pCR-HBVA1 1.3x. An additional 0.2 µg of pCMV-
GFP was added for the assessment of transfection efficiency. HBsAg secretion into 
the culture supernatants was measured using the Monolisa® Ag HBs Plus 
immunoassay kit (Bio-Rad, CA, USA).  Briefly, 100 µl of the cultured supernatants 
was incubated with an immobilised monoclonal HBsAg specific antibody for an hour 
at 37oC. After the hour incubation the plate was washed and developing solution 
added. The plate was allowed to develop at room temperature in the dark for 30 
minutes. After the 30 minutes incubation stopping solution was added and the ratio of 
the optical density at 450nm and 690 nm measured using Bio-Rad’s Model 680 
Microplate Reader (Bio-Rad, CA, USA).      
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2.4.2 Characterisation of pCR-HBVA1 1.3x targeted vector in vivo 
 
2.4.2.1 Hydrodynamic tail vein injections 
 
In vivo studies were carried out in accordance with protocols approved by the 
University of the Witwatersrand Animal Ethics Screening Committee (see last page of 
Appendix). Six to eight week old female mice were used for the experiments. To 
assess the replication competent plasmid pCR-HBVA1 1.3x, a mixture of 5 μg 
plasmid and saline comprising 10% of the mouse’s body mass was injected via the 
tail vein over 5 to 10 seconds.  Saline solutions containing three plasmid vectors 
pCR-HBVA1 1.3x, pCH-9/3091 or pCR-HBVA1 1x were injected into mice.  
The mice were bled on days 2 and 5 post-injection. Blood was collected by the retro-
orbital bleeding method. The blood was centrifuged at 3000 rpm at room temperature 
for 5 minutes and serum collected.  Animals were sacrificed on day 5 post-injection, 
and the livers harvested for RNA extraction. 
2.4.2.2 HBsAg and HBeAg secretion 
Serum collected from mice at days 2 and 5 post-injection were analysed for HBsAg 
and HBeAg secretion.  One hundred microlitres were used to quantify the amount of 
HBsAg and HBeAg secreted into mice sera. HBsAg levels were measured using the 
Monolisa® Ag HBs Plus immunoassay kit as described in Section 2.2.1.2. HBeAg 
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levels were measured using Axsym (Elisa) immunoassay Kits. The serology Unit of 
the National Health Laboratory Service (NHLS), Johannesburg, South Africa 
performed the HBeAg analysis. 
2.4.2.3 Viral particle equivalents 
One hundred microlitres of serum collected at days 2 and 5 post-injection were used 
to detect the HBV DNA levels (viral particle equivalents). Viral particles were 
extracted from serum on the MagNA Pure LC using the MagNA Pure LC Total 
Nucleic Acid Isolation Kit (Roche Diagnostics, Mannheim, Germany). PCRs were 
carried out on the extracted samples using the Roche Lightcycler 2.0 (Roche 
Diagnostics, Mannheim, Germany). Thermal cycling parameters consisted of a hot 
start (30 seconds at 95oC) followed by 50 cycles of PCR (denaturation at 95oC for 5 
seconds), annealing at 58oC for 10 seconds and extension at 72oC for 10 seconds, 
and finally melting curve analysis (95oC for 30 seconds, 65oC for 30 seconds, and 
95oC at 0.2oC/second ramp rate. Viral particle equivalents (VPEs) were determined 
using crossing point analysis with Roche software. VPEs were calculated using the 
WHO International Standards for quantitation of HBV DNA for Nucleic Acid 
Amplification Technology (NAT) assays (National Institute for Biological Standards 
and Control, UK). 
 
2.4.2.4 HBV mRNA measurement  
 
To measure the concentrations of HBV mRNA, total RNA was isolated from liver 
tissues (Appendix 6.1.7) and reverse transcribed using Sensiscript Reverse 
Transcription Kit (Qiagen, GmbH, Germany) according to the manufacturer’s 
instructions. To amplify HBV core, surface and housekeeping Glyceraldehyde-3-
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phosphate dehydrogenase (GAPDH) cDNA, the procedures and primers 
combinations described by Song and colleagues (70) were used (Table 2.4). All real-
time PCR was carried out using the Roche Lightcycler 2.0. Controls included water 
blanks and RNA extracts that were not subjected to reverse transcription. Taq 
readymix with SYBR green (Sigma, MO, USA) was used to amplify and detect DNA 
during the reaction. Thermal cycling parameters were the same as for viral particle 
equivalents (Section 2.2.2.3). Specificity of the PCR products was verified by melting 
curve analysis. Relative quantitation analysis was performed by determining the ratio 
of HBV RNA to GAPDH RNA.  
 
Table 2.4 Primer sequences for surface, core and GAPDH mRNA 
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2.5 Assessing efficacy of U6 shRNA cassettes against HBV   
 
2.5.1 Assessing efficacy of U6 shRNA in cultured mammalian cells  
 
2.5.1.1 Transfections  
 
Cell culture and transfections of Huh7 cells were carried out as described in Section 
2.2.1.1. To assess efficacy of U6 shRNA cassettes against the reporter plasmid, 0.4 
µg, 0.2 µg and 0.16 µg of pCH-FLuc was co-transfected with 0.9 µg, 1.1 µg and 1.14 
µg of U6 shRNA vectors. Addition of 0.2 µg phRL-CMV (Promega, WI, USA) allowed to 
correct for transfection efficiency. Efficacy of the shRNA expression cassettes against 
the replication-competent plasmid (as measured by HBsAg and HBV mRNA 
quantitation) was assessed by transfecting 0.25 µg of pCR-HBVA1 1.3x with 0.6 µg of 
U6 shRNA vectors. Addition of 0.2 µg of pCMV-GFP allowed for transfection 
efficiency to be determined. 
 
2.5.1.2 Assay for markers of viral replication in vitro 
 
Luciferase Assays  
 
Forty eight hours post-transfection cell lysate was prepared from cells transfected 
with pCH-FLuc and shRNA vectors. Luciferase activity was measured using the Dual 
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Luciferase® Reporter Assay System as described in Section 2.2.1.2 and Appendix 
6.1.5. 
 
HBsAg and relative HBV mRNA quantitation 
 
Forty eight hours post-transfection, 100 µl of culture medium was collected from cells 
cotransfected with pCR-HBVA1 1.3x and shRNA expression vectors and analysed for 
HBsAg secretion. Levels HBsAg was measured by ELISA as described previously 
(Section 2.2.1.2). Total RNA (Appendix 6.1.6.1) was isolated from cells to assess the 
level of HBV core and surface mRNA as well as GAPDH mRNA. The level of HBV 
mRNAs were analysed using the Roche Lightcycler 2.0 as described in Section 
2.4.2.4. 
 
2.5.2 Assessing efficacy of U6 shRNA in vivo 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
2.5.2.1 Murine hydrodynamic injections 
 
To assess efficacy of U6 shRNA cassettes against HBV in vivo, six to eight week old 
female mice were used. A saline solution comprising 10% of the mouse’s body mass 
was injected via the tail vein over a period of 5 to 10 seconds.  The saline solution 
contained a combination of three plasmid vectors: 5 μg target DNA (pCR-HBVA1 
1.3x), 5 μg anti HBV sequence (U6 shRNA encoding plasmid) and pCMV-GFP (for 
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delivery efficacy). The mice were bled on days 3, 5 and 7 post-injection. Serum was 
collected as described in section 2.2.2.1. Animals were sacrificed on day 7 post-
injection and their livers harvested for RNA extraction and immunohistochemical 
staining. Animal protocols were performed in accordance with the University of 
Witwatersrand Animals Ethics Screening Committee.  
 
2.5.2.2 Assay for markers of viral replication in vivo 
 
HBsAg and HBeAg secretions 
Serum collected at days 2, 5, and 7 after hydrodynamic tail vein injection were 
analysed for HBeAg and HBsAg using Axysym (ELISA) immunoassay kit and 
Monolisa® (Elisa) immunoassay kit, respectively. The serology unit of NHLS, 
Johannesburg, South Africa performed the HBeAg analysis. 
qPCR  
 
RNA was extracted from the liver of injected mice (Appendix 6.1.7 for extraction of 
RNA) at time of sacrifice.  HBV mRNA expression (core and surface mRNA) was 
analysed from total RNA using the Roche Lightcycler 2.0 as described in Section 
2.2.2.4. 
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Immunohistochemistry  
Approximately 4 g of liver was harvested and fixed for intrahepatic staining for HBcAg 
positive cells (Appendix 6.1.8). Cells positive for HBcAg stain brown as observed by 
Light Microscopy. 
 Statistical Analysis  
Analysis of statistically significant differences was carried out using the student’s 
paired two tailed t-test with the GraphPad Prism 4 software (GraphPad software, Inc., 
CA, USA) 
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Table 2.5:  Plasmids used in this study for transfection and injection  
 
____________________________________________________________________ 
 
Plasmid  Description     Reference/source 
 
pCH-FLuc          HBV plasmid surface ORF replaced by  
   Firefly Luciferase encoding sequence  Current study 
pCMV-GFP         Plasmid vector encoding Green Florence 
protein      (20) 
pCH-9/3091         Control HBV replication-competent plasmid (68) 
pCR-HBVa1 1x        HBVA1 non replication-competent plasmid MHRU Lab 
pCR-HBVa1 1.3x     HBVA1 non replication-competent plasmid Current study 
phRL-CMV         Plasmid  encoding Renilla luciferase  Promega, WI, USA 
pG-U6 shRNA 5       Plasmid encoding shRNA 5 sequences under  
        transcriptional control of the U6 promoter (48)  
pG-U6 shRNA 6       Plasmid encoding shRNA 6 sequences under  
          transcriptional control of the U6 promoter (48) 
pG-U6 shRNA 10     Plasmid encoding shRNA 10 sequences under  
          transcriptional control of the U6 promoter (48)  
 
 
 
 
 
 
Chapter 3  45 
CHAPTER 3 
3 RESULTS 
3.1 Generation of plasmid vectors of HBV  
3.1.1 Generation of a plasmid vector (pCH-FLuc) expressing Firefly luciferase 
as a marker of HBV replication.  
 
To generate a vector expressing Firefly luciferase as a marker of HBV replication, the 
preS2/S ORF of pCH-9/3091 was replaced with the sequence encoding Firefly 
luciferase (Figure 2.1), leaving all other ORFs intact. First, the Firefly luciferase 
sequence (1650 bp) was amplified from pCI-FLuc by PCR (Figure 3.1) to introduce 
the unique sites Xho I and Spe I. The amplified sequence was then cloned into the 
PCR cloning vector pTZ-57R/T. Clones positive for insert were identified by restriction 
with Xho I and Spe I. As indicated in Figure 3.2 several clones were positive for 
inserts of the desired size (i.e. 1650 bp). To replace the preS2/S ORF of pCH-9/3091 
with the sequence encoding Firefly luciferase, pTZ-FLuc was restricted with Xho I and 
Spe I (Figure 3.3). The preS2/S was removed from pCH-9/3091 by first completely 
restricting the plasmid with Xho I followed partial digestion with Spe I (Figure 3.4). 
Finally the Xho I-Spe I restricted Firefly luciferase fragment was ligated into the Xho I-
Spe I sites of pCH-9/3091. To confirm successful insertion of the Firefly luciferase 
sequence into pCH-9/3091 the resulting clones were screened with Xho I and Spe I 
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digestion.  A single clone was positive for insertion. This clone was further analysed 
by restriction enzyme digestion (Figure 3.4). The results from Figure 3.4 confirm 
successful cloning of the sequence encoding Firefly luciferase into the position 
previously occupied by the PreS2/S. 
 
 
 
 
Figure 3.1:  Agarose gel electrophoresis of the purified Firefly luciferase PCR product. A 1 kb 
DNA ladder was used as a molecular weight marker.  
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pTZ-Fluc
4582 bp
Firefly luciferase
Spe I (2338)
XhoI (657 )
   
 
 
Figure 3.2: Screening for the presence of the Firefly luciferase insert. Plasmid DNA from colonies positive for an insert were 
restricted with Xho I and Spe I to confirm the presence of the Firefly luciferase sequence. Lanes 1 and 12:  Molecular weight 
markers, lane 2: Undigested pTZ-FLuc clone, lanes 3 – 11 DNA from clones 1-10 restricted with Spe I and Xho I.  Asterisk 
indicates putative positive clones. 
 
 
* * * * * 
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Figure 3.3 Agarose gel electrophoresis of the pCH-9/3091 first completely restricted with Xho I followed partial digestion with 
Spe I.  Lane 1: O’GeneRuler DNA ladder, Lane 2 pCH-9/3091 completed digested with Xho I, lane 3 -7 Xho I restricted pCH-
9/3091 serially digested with decreasing concentrations of  Spe I. Arrows indicates the isolated fragment.  
 
 
 
pC H-9/3091
6338 bp
Surface ORF
XhoI ( 1497 )
SpeI ( 2049)
SpeI ( 57 58)
 
 
pCH-9/3091 
Chapter 3  49 
pC H-FLuc
7 467  bp
Firefly luciferase
XhoI ( 1497 )
PstI ( 687 8)
SpeI ( 317 8)
SpeI ( 6887 )
SacI ( 4499)
Sac I ( 7456)
Sca I ( 1690)
Sca I ( 5134)
XbaI ( 178)
XbaI ( 329)
  
 
Figure 3.4 Screening for Firefly luciferase sequence insertion into PreS2/S ORF of pCH-9/3091.  Lane 1 and 12: 
O’GeneRuler DNA ladder, lanes 2 and 3: undigested plasmids, lanes 4 and 5: Xho I-Spe I digestions, lanes 6 and 7: 
Sca I digestion, lanes 8 and 9: Pst I-Sac I digestions lans 10 and 11: Xba I digestion. 
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3.1.2 Generation of a replication competent plasmid (pCR-HBVA1 1.3x) 
containing a greater than genome sequence of the viral A1 subgenotype.   
 
Figure 2.2 shows the strategy for the creation of a vector containing a greater than 
genome length sequence of HBV subgenotype A1. The BCP (787 bp) and pA (182 
bp) sequences were amplified from pCR-HBVA1 1x by PCR (Figure 3.5). 
Amplification introduced the unique sites Hind III and Pci I into the BCP sequence and 
Fsp I and Apa I into the pA sequence. The amplified sequences were then cloned into 
pTZ-57R/T to generate pTZ-BCP and pTZ-pA.  Clones positive for inserts were 
screened by restriction with Hind III-Pci I (pTZ-BCP) and Fsp I-Apa I (pTZ-pA).  The 
restriction analysis of the DNA isolated from positive clones showed that the BCP and 
pA sequences had been correctly inserted into the pTZ-57R/T vector and inserts were 
of desired sizes (i.e. 787 bp and 182 bp) (Figures 3.6 and 3.7). To generate a greater 
than genome length sequence of HBV subgenotype A1, pCR-HBVA1 1x was 
restricted with Hind III and Apa I (full length sequence of HBV fragment) and with Fsp 
I and Pci I (pCR-XL-TOPO plasmid backbone fragment) (Figure 3.8).  Finally the Hind 
III-Pci I restricted BCP fragment and Fsp I-Apa I restricted pA fragment were ligated 
together with the Hind III-Apa I and Fsp I-Pci I  fragments from pCR-HBVA1 1x. To 
confirm successful insertion of BCP and pA sequences into pCR-HBVA1 1x, clones 
were restricted with Hind III and Apa I (Figure 3.9). These results confirm successful 
cloning of the BCP sequence and the pA sequence upstream and downstream of full 
length sequence of HBV subgenotype A1, respectively. 
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Figure 3.5:  Agarose gel electrophoresis of the purified pA and BCP PCR products. Lane 1: 
500 bp DNA ladder was used as a molecular weight marker, lane 2: pA amplicon and lane 3: 
BCP amplicon.  
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pTZ-BC P
3689 bp
BCP
HindIII (557 )
HindIII (1494)
PciI ( 1345)
PciI ( 1880)  
 
Figure 3.6:  Screening for the successful insertion of the BCP fragment into pTZ-57R/T.  Lane 1 and 12: 1 kb and 500 bp 
DNA ladder, lane 2–11 pTZ-BCP clones digested with a combination of Hind III and Pci I restriction enzymes.  All clones are 
positive clones in figure legend. 
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pTZ-pA
2886 bp
pA
ApaI ( 665)
FspI ( 480)
FspI ( 2192)
 
 
Figure 3.7:  Screening for the successful insertion of the pA sequence into pTZ-57R/T.  Lane 1 and 12: 1 kb and 500 bp 
DNA ladder, lane 2–11 pTZ-pA clones digested with a combination of  Apa I and Fsp I restriction enzymes.  All clones are 
positive in figure legend.  
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pC R-HBV  A1 1x
67 81 bp
HBV A1
HindIII (27 7 )
ApaI ( 3661)
SpeI ( 301)
SpeI ( 1037 )
PciI ( 2208)
PciI ( 6657 )
FspI ( 2160)
FspI ( 3831)
FspI ( 47 30)
 
 
 
Figure 3.8: Agarose gel electrophoresis of pCR-HBV1 1x restricted for (A) full length sequence of HBV and (B) vector 
backbone (pCR-XL- TOPO backbone). (A) lane 1: O’GeneRuler DNA ladder, lane 2-5 pCR-HBVA1 1x digestion (Hind III-Apa 
I-Spe I). (B) Lane 1-4: pCR-HBVa 1x digestion (Fsp I and Pci I), lane 5 O’GeneRuler DNA ladder. The 3200 bp HBV and 178 
bp pA insert can be seen in the restriction analysis from all ten clones. 
pCR-HBVA1 1x 
 
 Hind III /Apa I  / Spe I 
pCR-HBVA1 1x 
 
Fsp I / Pci I  
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pC R-HBV  A 1 1.3x
7 543 bp
BCP
HBV A1
pA
HindIII (27 7 )
ApaI (4423)
 
 
Figure 3.9: Screening for the presence of both BCP and pA inserts. Clones were selected and DNA was digested to confirm 
the presence of BCP and pA. Lane 1: O’GeneRuler DNA ladder, lane 2 undigested pCR-HBVA1 1.3x clone, lane 3, 4, 8–12 
positive clones, lane 5 and 7 looks like undigested clones, lane 6 and 13 erroneous clones. Asterisk indicates putative 
positive clones. 
 
 
* * * * * * * 
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3.2. Expression of Firefly luciferase as a marker of HBV replication in cultured 
mammalian cells. 
 
To express luciferase as a marker of HBV replication, the surface ORF of pCH-
9/3091 was replaced with the sequence encoding Firefly luciferase (Figure 2.1). To 
assess functionality of this construct (pCH-FLuc), it was co-transfected with a phRL-
CMV (plasmid expressing Renilla luciferase) in cultured mammalian cells (Huh7). A 
plasmid expressing EGFP was also included to control for transfection efficiency. As 
can be seen from Figures 3.10 A and 3.10 B equal expressions of green cells indicate 
that transfection efficiency was equivalent. Figure 3.10 C shows Firefly luciferase 
activity in transfected cells. From the figure it is evident that cells transfected with 
pCH-FLuc expressed Firefly luciferase whereas the mock transfected cells did not 
(Figure3.10). The results demonstrate that Firefly luciferase is expressed within the 
HBV genome construct of the pCH-FLuc vector. 
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Figure 3.10: Luciferase expression in Huh7 cells. The transfection was performed in triplicate 
and the quantities of luciferase were analysed by the Dual Luciferase Reporter Assay 
System. Fluorescence microscopy fields of Huh7 cells transfected with (A) pCH-FLuc and 
pCMV-GFP (B), pCMV-GFP only (C), Luciferase activity in Huh7 cells transfected with pCH-
Fluc. 
 
C 
C 
  
B 
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3.3 Assessing functionality of the replication competent plasmid derived from 
HBV subgenotype A1 (pCR-HBVA1 1.3x)  
 
3.3.1 Cells transfected with pCR-HBVA1 1.3x   
 
To assess functionality of pCR-HBVA1 1.3x it was transfected into cultured 
mammalian cells and HBsAg secreted into culture medium measured. pCH-9/3091 
was used a control positive for HBsAg secretion. The negative control included pCR-
HBVA1 1x to confirm that any observed HBsAg was due to presence of BCP and pA. 
An EGFP expressing plasmid was utilised to standardise transfection efficiency 
(Figure 3.11 A). Cells transfected with pCR-HBVA1 1.3x and pCH-9/3091 strongly 
expressed HBsAg, whereas cells transfected with pCR-HBVA1 1x exhibited a small 
increase in HBsAg level (Figure 3.11E).  The small increase of HBsAg may be due to 
a unique internal promoter that is specific for HBV surface antigen expression. No 
HBsAg was detected in the culture supernatant from untreated cells. The results 
demonstrate that pCR-HBVA1 1.3x was able to express HBsAg in cultured 
mammalian cells.  
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Figure 3.11: HBsAg secretion in transfected cells in culture. Fluorescence microscopy fields 
of (A) Huh7 cells only, and cells transfected with (B) pCR-HBVA1 1x (C), pCH-9/3091 and (D) 
pCR-HBVA1 1.3x. (E) HBsAg secretion from Huh7 cells transfected with HBV plasmids. 
HBsAg measurements by ELISA. The transfection was performed in triplicate and the bars 
indicate the standard error of the mean (SEM). 
 
 
E 
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3.3.2 Expression of markers of HBV replication in vivo 
 
3.3.2.1 HBsAg and HBeAg secretion in vivo 
 
To assess HBsAg and HBeAg secretion in vivo, pCR-HBVA1 1.3x, pCR-HBVA1 1x, 
or pCH-9/3091 were delivered to the livers of mice using the hydrodynamic tail vein 
injection procedure. pCR-HBVA1 1.3x and pCH-9/3091 both effect secretion of 
HBsAg and HBeAg in the serum of mice as measured at days 3 and 5 (Figure 3.12). 
Mice injected with pCR-HBVA1 1x did not secrete significant amounts of HBsAg at 
days 3 and 5. Each experiment comprised 3 groups of animals. The data confirm that 
the presence of markers of HBV replication are due to the greater than genome 
length of pCR-HBVA1 1.3x. These results support our previous findings in transfected 
cells where secretion HBsAg into the culture supernatant was demonstrated. 
Importantly secretion of HBeAg demonstrates that pCR-HBVA1 1.3x enables viral 
replication and not merely gene expression to occur.  
 
3.3.2.2 Serum viral particle equivalents in vivo 
 
To assess the production of viral particle equivalents, pCR-HBVA1 1.3x, pCR-HBVA1 
1x or pCH-9/3091 were delivered to the livers of mice using the hydrodynamic tail 
vein injection procedure. The serum viral particle equivalents (Figure 3.13) exhibited a 
similar trend to that seen with HBsAg and HBeAg secretion, confirming the previous 
results.  The level of serum viral particle equivalents was increased in mice injected 
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with the replication competent constructs (pCR-HBVA1 1.3x) and pCH-9/3091 at days 
3 and 5.  However, mice injected with pCR-HBVA1 1x did not have significant 
detectable levels of viral particle equivalents.  
 
3.3.2.3 HBV mRNA expression in vivo 
The HBV genome has four primary overlapping ORFs which code for the surface, 
core, polymerase and HBx proteins (Figure 1.2). Transcription from the four ORFs 
results in formation of the pregenomic RNA and the three subgenomic mRNAs. To 
assess expression of these transcripts, RNA extracted from livers of mice 
hydrodynamically injected with pCR-HBVA1 1.3x, pCH-9/3091 and pCR-HBVA1 1x 
were subjected to RT-PCR. Figure 3.14 reveals that injection with pCR-HBVA1 1.3x 
causes expression of HBV mRNA levels equivalent to that achieved with the positive 
control, pCH-9/3091. Mice injected with pCR-HBVA1 1x did not exhibit significantly 
increased levels of core or surface HBV mRNA at day 5.   
These results demonstrate that pCR-HBVA1 1.3x was able to express HBsAg, 
HBeAg, viral particle equivalents, as well as core and surface HBV mRNA in vivo.  
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Figure 3.12: HBsAg and HBeAg measurement in the hydrodynamic injection model of HBV 
replication. Serum (A) HBsAg, (B) HBeAg levels were determined at day 3 and 5 after 
hydrodynamic injection of mice with pCR-HBVA1 1x, pCH-9/3091 and pCR-HBVA1 1.3x. 
Results of HBsAg (A) were normalised relative to pCR-HBVA1 1.3x. Results are expressed 
as the mean (SEM) from at least three mice. 
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Figure 3.13: HBV serum viral particle equivalents in the hydrodynamic injection model of 
HBV replication. VPEs at day 3 and 5, after hydrodynamic injection with pCR-HBVA1 1x, 
pCR-HBVA1 1.3x and pCH-9/3091. Groups comprised 3 animals and the graphs indicate the 
mean and SEM for each group. 
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Figure 3.14: HBV mRNA measurement for core (A) and surface (B) in the hydrodynamic 
injection model. Hepatocyte concentrations of HBV mRNA from the core and surface regions 
expressed as a ratio to amount of GAPDH mRNA. Total RNA was isolated from liver cells at 
day 5 after hydrodynamic injection and subjected to quantitative real-time PCR. Groups 
comprised 3 animals and the graphs indicate the mean and SEM for each group. 
A 
B 
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3.4 Inhibition of HBV replication by activating RNA interference with 
U6 shRNA sequences 
 
3.4.1 Inhibition of HBV replication in cultured mammalian cells 
 
3.4.1.1 Effects of U6 shRNA sequence on luciferase activity in transfected cells 
 
To assess the effects of U6 shRNA sequences on luciferase expression, pCH-FLuc 
was co-transfected with U6 shRNA 5, U6 shRNA 6 and U6 shRNA 10 at different 
effecter to target ratios (48). Plasmids expressing Renilla luciferase and EGFP were 
transfected to ascertain transfection efficiency. Luciferase activity decreased by 
approximately 50%, 70% and 80% when treated with U6 shRNA 5 and U6 shRNA 6 
at the different ratios, whereas treatment with U6 shRNA 10 did not significantly alter 
Firefly luciferase activity (Figure 3.15). These results demonstrate a reduction in 
Firefly luciferase expression in cultured mammalian cells after treatment with U6 
shRNA 5 and U6 shRNA 6. These results correlate with data of Carmona and 
colleagues (48). Firefly luciferase is not susceptible to knockdown by U6 shRNA 5 
and 6. U6 shRNA 5, U6 shRNA 6 and U6 shRNA 10 all target the HBx ORF region. 
Firefly luciferase activity is diminished upon administration of expression cassettes 
producing these shRNAs, and indicates that reporter gene activity correlates with 
HBV gene expression. 
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Figure 3.15: Luciferase measurements in Huh7 cells treated with shRNA sequences. Schematic illustration of plasmid 
construct pCH-Fluc showing ORFs, respective transcripts and sites targeted by U6 shRNA 5, U6 shRNA 6 and U6 shRNA 10 
(A). Microscopy fields of Huh7 cells co-transfected with pCMV-GPF and pCH-Fluc with no U6 shRNA (BA), U6 shRNA 5 
(BB), U6 shRNA 6 (BC), U6 shRNA 10 (BD). Huh7 cells were transfected with 0.4, 0.2, 0.16 µg of pCH-FLuc together with 
0.9, 1.1, 1.14 µg of U6 shRNA 5 or shRNA 6 or shRNA 10. (C) Firefly luciferase activity was normalised to Renilla luciferase 
activity. The data were determined from three independent experiments and are expressed as the mean with SEM. 
 
E 
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3.4.1.2 Effects of U6 shRNA sequence on HBsAg secretion from transfected 
cells 
 
To assess the effects of shRNA sequences on HBsAg secretion in cells receiving the 
HBVA1 replication-competent plasmid, pCR-HBVA1 1.3x was co-transfected with U6 
shRNA 5, U6 shRNA 6 or U6 shRNA 10. Cells treated with U6 shRNA 5 and U6 
shRNA 6 were able to reduce HBsAg levels significantly, whereas cells treated with 
U6 shRNA 10 showed little or no significant knockdown of HBsAg secretion (Figure 
3.16). The mock transfection, receiving no effecter, did not exhibit an effect on HBsAg 
concentrations, indicative of the inhibitory effects and specificity of the shRNA 5 and 6 
sequences.  
 
3.4.1.3 Effects of U6 shRNA sequence on HBV mRNA from transfected cells 
To confirm that the effect of shRNA 5 and 6 on HBsAg expression was through the 
reduction of HBV RNA levels, we performed quantitative RT-PCR analysis with RNA 
extracted from Huh7 cells co-transfected with pCR-HBVA1 1.3x and U6 shRNA 
sequences. The observation revealed that treatment with U6 shRNA 5 and 6 resulted 
in a decrease of both core and surface mRNAs by 95-100%, compared with the 
untreated cells (Figure 3.17). Treatment with U6 shRNA 10 exhibited no significant 
decrease of both core and surface mRNAs. Again this observation correlates with 
previous work by Carmona and colleagues (48).  
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Figure 3.16: HBsAg measurement in the Huh7 cells treated with shRNA sequences. 
Representative fluorescence microscopy fields of Huh7 cells co-transfected with GFP 
expressing plasmid and pCR-HBVA1 1.3x together with U6 shRNA cassette. (A) pCR-HBVA1 
1.3x, (B) U6 shRNA 5, (C) U6 shRNA 6, and (D) U6 shRNA 10. (E) HBsAg secretion as 
measured by ELISA. The experiments were done in triplicate and the error bars indicate the 
SEM.  
E 
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Figure 3.17: HBV mRNA measurement in the Huh7 cells treated with shRNA sequences. Hepatocyte concentrations of HBV 
mRNA from the (A) surface, and (B) core regions expressed as a ratio to amount of GAPDH mRNA.  Total RNA was isolated 
from Huh7 cells 48 hr after transfection of pCR-HBVa1 1.3x together with shRNA sequence. The transfection was performed 
in triplicate and the bars indicate mean SEM.               
 
A B 
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3.4.2 Inhibition of HBV replication in vivo  
 
3.4.2.1 Effects of U6 shRNA sequence on HBsAg and HBeAg secretion using 
the hydrodynamic mouse model of HBV replication 
 
To determine anti HBV efficacy of U6 shRNA sequences on HBsAg and HBeAg 
secretion in vivo, pCR-HBVA1 1.3x together with U6 shRNA 5, U6 shRNA 6 or U6 
shRNA 10 were delivered to the livers of mice using the hydrodynamic tail vein 
injection procedure. U6 shRNA 5 and 6 both show strong inhibition of HBsAg 
secretion at days 3, 5 and 7 (Figure 3.18). The HBeAg concentration was also 
significantly knocked down by U6 shRNA 5 and 6 at day 7 (approximately 90–100%) 
(Figure 3.19). U6 shRNA 10 exhibited no significant inhibition of HBsAg and HBeAg in 
vivo, which supports the in vitro results. This data correlate with the published work of 
Carmona and colleagues (48)  
 
3.4.2.2 Effects of U6 shRNA sequence on HBV mRNA in vivo 
To confirm that the effect of U6 shRNA 5 and 6 on HBsAg expression was through 
the reduction of HBV RNA levels in vivo, we performed quantitative RT-PCR analysis 
with RNA extracted from mouse livers, 7 days after mice were hydrodynamically 
injected with pCR-HBVA1 1.3x together with U6 shRNA 5, U6 shRNA 6 or U6 shRNA 
10. The U6 shRNA 5 and U6 shRNA 6 vectors decreased the expression of both core 
and surface mRNAs by 95-100% (Figure 3.20).  
Chapter 3  71 
3.4.2.3 Effect of U6 shRNA sequence on intrahepatic HBcAg expression  
 
HBcAg, the nucleocapsid protein, is synthesised in infected cells and is required for 
HBV viral replication. To confirm that the effect of U6 shRNA 5 and 6 on HBsAg, 
HBeAg and mRNA expression was due to an effect of viral replication, we performed 
immunohistochemical staining for HBcAg in tissue sections from mice. 
Immunohistochemical staining for HBcAg in liver tissue from U6 shRNA 5, U6 shRNA 
6 and U6 shRNA 10 infected mice allowed us to directly observe HBV clearance from 
hepatocytes. Fixed liver sections harvested from mice 7 days after injection were 
stained for HBcAg, and visualized under a light microscope. Liver sections from HBV 
transgenic mice were also stained. HBV transgenic mice replicate the virus at levels 
comparable to that in the infected livers of patients with chronic hepatitis (35). 
Sections from  transgenic mice and mice injected with pCH-HBVA1 1.3x show 
numerous HBcAg positive cells, whereas mice treated with U6 shRNA 5 and 6 show 
no HBcAg positives cells at day 7 (Figure 3.21). Mice treated with control U6 shRNA 
10 sequences did not significantly reduce the HBcAg positive cells. The results 
demonstrate that U6 shRNA 5 and U6 shRNA 6 were able to inhibit expression of 
HBsAg, HBeAg, HBcAg and mRNA of HBV in vivo. 
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Figure 3.18: HBsAg measurement from serum of mice hydrodynamically injected with pCR-HBVA1 1.3x and shRNA 
sequences. Serum HBsAg concentrations were determined at days 3, 5 and 7. Groups comprised 3-5 animals and the 
graphs indicate the mean and SEM for each group.
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Figure 3.19: HBeAg measurement from mice hydrodynamically injected with pCR-HBVA1 
1.3x and shRNA sequences. Serum HBeAg concentrations were determined at day 7 after 
injection. Groups comprised 3-5 animals and the graphs indicate the mean and SEM for each 
group. 
 
Chapter 3  74 
 
 
                    
Figure 3.20: HBV mRNA measurement from mice hydrodynamic injection with pCR-HBVA1 1.3x and shRNA sequences. 
Hepatocyte concentrations of HBV mRNA from the (A) core, and (B) surface regions expressed as a ratio to amount of 
GAPDH mRNA. Total RNA was isolated from mouse livers at day 7 after hydrodynamic injection of pCR-HBVA1 1.3x 
together with shRNA sequences and subjected to RT-PCR. Groups comprised 3-5 animals and the graphs indicate the 
mean and SEM for each group.
B A 
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Figure 3.21: Immunohistochemical staining for HBcAg in liver sections from hydrodynamic 
injection model of HBV replication. (A1 and A2) HBV transgenic mouse, (B1 and B2) mouse 
with pCR-HBVA1 1.3x only, (C1 and C2) mouse treated with U6 shRNA 10, (D1 and D2) 
mouse treated with U6 shRNA 5, (E1 and E2) mouse treated with U6 shRNA 6. Mice 
subjected to the hydrodynamic injection procedure were sacrificed after 7 days and the livers 
analysed using immunohistochemistry to detect the HBcAg. Representative data, High- and 
low-power fields are shown for livers from pCR-HBVA1 1.3x together with shRNA sequences. 
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CHAPTER 4 
4 DISCUSSION  
 
The study of gene therapy against HBV infection is hampered by the lack of useful 
research models. This is also true for chronic HBV infection in southern Africa, in 
which HBV subgenotype A1 is hyperendemic and associated with high incidence of 
liver cancer and cirrhosis. The data presented in this study as well as other studies 
demonstrate the potential for the development of vectors for the study of HBV 
replication in vitro and in vivo.  These vectors can be used to assess potential 
therapeutic strategies (such as RNAi against HBV) against regionally significant 
subgenotypes of HBV. 
 
4.1   Replication competent vectors of HBV 
 
The ability to generate greater than genome length constructs capable of HBV 
replication and gene expression at levels comparable to that in naturally infected liver 
has been shown to be dependent on unique cloning criteria.  Guidotti and colleagues 
(35) identified the criteria that can increase HBV expression and replication both in 
vitro and in vivo. The construct was successfully generated by cloning the HBV 
promoter (with Enhancer I and II) immediately upstream of a complete viral genomic 
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sequence and the unique polyadenylation signal immediately downstream of the full 
genome. These criteria were also shown to be necessary for tissue specificity in that, 
high levels of HBV replication and gene expression were achieved in the liver tissues. 
Similarly, pCR-HBVA1 1.3x was generated using the same criteria to repeat the BCP 
sequence upstream and the polyadenylation sequence downstream of the full-length 
HBV sequence.   
 
In vitro and in vivo analysis of pCR-HBVA1 1.3x and pCR-HBVA1 1x revealed that 
pCR-HBVA1 1.3x was able to increase levels of HBV expression and replication in 
liver whereas pCR-HBVA1 1x are defective for viral replication.  In principle, HBV 
replication requires the BCP and pA sequences to be repeated upstream and 
downstream of a full length HBV sequence. pCR-HBVA1 1.3x demonstrates the 
potential of these vectors for the study of HBV replication and gene expression as 
well as the assessment of potential therapeutic agents against HBV infection.  
 
4.2. Reporter plasmids 
 
To facilitate studies on viral replication particularly when assessing potential 
therapeutic agents against HBV the generation of vectors expressing reporter 
proteins as markers of HBV replication can expedite analysis of therapeutic accuracy 
and efficiency. Numerous studies show that reporter proteins such as β-galatosidase, 
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EGFP and Luciferase (71) can be used to assess expression of genes of interest. 
The same principle can be applied to analysis of HBV gene expression.  
 
Passman and colleagues (20) demonstrated that replacing the surface ORF of pCH-
9/3091 with the sequence encoding enhanced Green Fluorescent Protein (EGFP) 
generated a vector capable of expressing EGFP as a marker of HBV replication. 
Similarly, in this study pCH-FLuc was generated using a technique to insert the Firefly 
luciferase gene into the position previously occupied by surface ORF. In vitro analysis 
of cells transfected with pCH-FLuc showed high expression of Firefly luciferase. 
Commercially available Dual Luciferase assays allows for the co-transfection of 
constitutively active Renilla luciferase expressing vector, which allows for 
normalisation of Firefly luciferase activity thereby improving the accuracy of this 
reporter system.  
 
Use of this vector allows for rapid assessment of antiviral efficacy as compared to 
techniques such as real-time PCR. This vector by no means supplants vectors such 
as pCR-HBVA1 1.3x but it does allow for the rapid screening of large data sets. 
Employing a reporter plasmid has additional advantage in that it overcomes the 
problem of HBV mutants that are not detected by commercial immunoassays and 
allows for accurate quantitation of viral expression. 
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4.3 RNAi against HBV replication 
 
That RNAi can be utilised to therapeutic effect against HBV has been well 
documented (9, 48, 64, 66, 67, 72). Other areas in this field still need to be explored, 
such as the efficacy of RNAi against regionally significant subgenotypes of HBV (e.g. 
A1) and the utility of using a surrogate reporter plasmid of HBV to screen efficacy of 
RNAi sequences. 
                        
4.3.1 shRNA against replication competent vectors of HBV 
 
Carmona and colleagues (48) generated 10 U6 encoded short hairpin (U6 shRNAs) 
that target conserved sequences of the oncogenic HBx open reading frame of pCH-
9/3091. Of these hairpins, U6 shRNA 5 and U6 shRNA 6 were selected in this study 
as these were shown to significantly knockdown markers of HBV replication in 
transfected hepatocytes and in a murine hydrodynamic injected model of HBV 
replication. U6 shRNA 10 was also used as it does not cause significant knockdown 
of markers of HBV replication.  The hairpins were used to test for local SA HBV 
isolates (HBV subgenotype A1). Similarly, co-transfection of U6 shRNA 5 and U6 
shRNA 6 with an HBV replication competent vector (pCR-HBVA1 1.3x) led to a 
significant reduction in viral mRNA expression and viral protein production in 
mammalian cells.  The U6 shRNA 10 did not efficiently inhibit replication of the virus.  
In a murine hydrodynamic injection model of HBV replication, both U6 shRNA 5 and 
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U6 shRNA 6 caused significant inhibition in markers of HBV replication to near 
baseline levels and U6 shRNA 10 did not inhibit replication of the virus.  This effect 
was sustained for 7 days.  Immunohistochemical staining of liver sections revealed a 
strong association between the decline of HBV serum marker levels by U6 shRNA 5 
and U6 shRNA 6. U6 shRNA 10 did not cause any significant histological changes in 
liver tissues from that observed in the mock treatments.  
 
4.3.2 shRNA against reporter plasmids  
 
The reporter plasmid (pCH-FLuc) enabled rapid assessment of antiviral efficacy in 
vitro. Co-transfection of U6 shRNA 5 and U6 shRNA 6 with the reporter plasmid led to 
a significant reduction of Firefly luciferase activity, whereas U6 shRNA 10 did not 
decrease the level of luciferase expression. In vitro studies transfecting pCH-FLuc 
with different amounts of the U6 shRNA-expressing plasmids showed significant 
decreases in Firefly luciferase expression by U6 shRNA 5 and U6 shRNA 6. Again U6 
shRNA 10 did not decrease the level of luciferase expression at any dose.  These 
data show that low doses of U6 shRNA 5 and U6 shRNA 6 caused significant 
decrease Firefly luciferase activity in mammalian cell culture. That Firefly luciferase 
activity is diminished upon administration of these shRNA expressing plasmids 
indicates that expression of these RNAi sequences correlates with HBV gene 
expression.   
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Both U6 shRNA 5 and U6 shRNA 6 were equally capable of inhibiting Firefly 
luciferase expression whereas U6 shRNA 10 was unable to inhibit replication of the 
virus. This data correlates with previous findings by Carmona and colleagues (48).   
 
Further improvements of this model of HBV replication, such as the generation of 
stable cell lines and transgenic mice are necessary to assess potential therapeutic 
strategies against regionally significant subgenotypes of HBV. Development of 
delivery vehicles (viral and non viral vectors) as options for the effective deployment 
of siRNA or shRNA also need to be improved to increase the overall efficacy of this 
anti HBV treatment modality. Generation of siRNA that can induce interferon 
expression is also a major challenge in the field of RNAi pathways. 
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CHAPTER 5 
5 CONCLUSION 
In summary, we have demonstrated that the replication competent vectors of HBV 
(pCR-HBVA1 1.3x and pCH-FLuc) can recapitulate HBV replication in vitro and in 
vivo.  Our results also show that anti HBV effecter sequences (U6 shRNA) inhibit viral 
gene expression, replication and reporter plasmid efficiently, both in vitro and in vivo.  
 
The presence of the BCP and pA sequences in pCR-HBVA1 1.3x allowed this 
plasmid to simulate viral replication in vitro and in vivo. Mice injected with pCR-
HBVA1 1.3x were able to express significant levels HBsAg, HBeAg, viral particles, as 
well as surface and core mRNA when compared to control vectors and indicate that 
the plasmid is replication competent. The ability of pCH-FLuc to express Firefly 
luciferase was tested in cultured mammalian cells. U6 shRNA 5 and U6 shRNA 6 
(which are targeted to the HBx ORF) were able to specifically reduce HBV gene 
expression, replication and reporter gene expression both in vitro and in vivo. U6 
shRNA 10 was unable to inhibit markers of HBV replication. These findings are in 
accordance with previous studies (48). The strategy presented in this study 
demonstrates the potential for the development of vectors for the study of HBV 
replication as well as the assessment of potential therapeutic strategies of regionally 
significant subgenotypes of HBV. 
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Future work will involve analysing intracellular viral replication intermediates, 
establishment of stably transfected liver cell lines producing HBV and also a 
transgenic mouse replicating HBV at a level similar to that found in chronic carriers of 
this virus. 
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6 APPENDICES  
 
6.1. APPENDIX A: LABORATORY PROTOCOLS 
6.1.1 Preparation of chemically competent E.coli and Transformation 
Reagents 
Luria-Bertani (LB) medium  
Ten grams of Tryptone (Oxoid, UK.), 5 g Yeast Extract (Oxoid, UK) and NaCl 
were dissolved in 1 litre of deionised water. LB medium was sterilised by 
autoclaving for 20 minutes at 121°C and 1 kg/cm2 and stored at room 
temperature. 
Transformation buffer   
Transformation buffer contained 100 mM CaCl2, 10 mM PIPES-HCl and 15% 
Glycerol (the pH was adjusted to 7.0 with NaOH). The solution buffer was 
sterilised by autoclaving for 20 minutes at 121°C and 1 kg/cm2. Transformation 
buffer was stored at -20°C. 
Protocol  
Preparing chemically competent E. coli 
Luria Broth (LB, 10 ml) was inoculated with glycerol stocks of E. coli (50 μl). 
The inoculum was incubated at 37°C overnight, diluted (1:10) and grown to an 
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A600 of approximately 0.4. The cells were centrifuged (2000xg, 10 minutes) and 
pellets resuspended in transformation buffer (10 ml per 100 ml culture). The 
suspension was left on ice for 20 minutes, centrifuged (1500xg, 10 minutes) 
and the pellet resuspended in transformation buffer (1 ml). Aliquots (50 μl) of 
competent cells were stored at -70°C.  
Reagents 
1000x Ampicillin or Kanamycin 
One hundred milligrams of ampicillin (Roche, Germany) was dissolved in 1 ml  
of 50% ethanol.  
Luria Bertani agar plate (Ampicillin or Kanamycin plate)  
Bacterial plates were prepared containing 1% (w/v) Agar (Oxoid, UK) in LB 
medium. The mixture was autoclaved for 20 minutes at 121°C and 1 kg/cm2 
then cooled to 50°C. Ampicillin or kanamycin was added to a final 
concentration of 100 μg/ml of Luria Bertani agar solution.  Luria Bertani agar 
plates were prepared by pouring the solution into Petri dishes and allowing 
agar to solidify at room temperature.  Plates were stored at 4°C. 
Protocol 
Transforming chemically competent E. coli cells                                                   
For cell transformation, frozen stocks were thawed gently in ice and plasmid 
was added.  The mixture was incubated on ice for 20 minutes and then heat-
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shocked at 42°C for 90 seconds. The samples were transferred to ice and 
incubated for a further 2 minutes. Transformed bacteria were plated on agar 
plates containing ampicillin or kanamycin. 
Reagent  
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) stock solution. 
Twenty milligrams of X-gal (Sigma, MO, USA) was dissolved in 1 ml dimethyl 
formamide. The solution is light sensitive and is therefore covered with 
aluminium foil and stored at -20°C.  
Protocol 
Preparation of X-gal positive Luria Bertani agar plates 
To prepare X-gal positive Luria Bertani agar, 40 µl of X-gal and 8 µl of IPTG 
stock solution were added to ampicillin or kanamycin plates and spread evenly 
on the surface. The plates were dried in an incubator at 37°C for 30 minutes 
and stored at 4°C. Transformed E.coli cells were plated on ampicillin or 
kanamycin positive, X-gal, IPTG positive agar plates and incubated at 37°C 
overnight. IPTG induces expression of β-galactosidase, which cleaves the 
chromogenic substrate X-gal to yield a blue product. Successful cloning 
(plasmid positive for an insert) disrupts the β-galactosidase gene and therefore 
the protein is not functional resulting in white colonies. Unsuccessful insert of 
fragments leaves the β-galactosidase intact resulting in blue colonies.    
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6.1.2 EndoFree® plasmid maxi kit plasmid preparation (Qiagen, GmbH, 
Germany). 
 
Reagents  
Luria Bertani Medium (See Appendix 6.1.1) 
1000x Ampicillin or Kanamycin (See Appendix 6.1.1) 
Protocols 
Two hundred and fifty milliliters of Luria Bertani medium was inoculated with a 
single colony containing the plasmid of interest and incubated at 37°C with 
shaking (100 rpm) overnight. The cells were pelleted by centrifugation at 6000 
rpm for 15 minutes at 4°C and the pellet resuspended in 10 ml Buffer P1 
containing RNAse A at a concentration of 100 µg/ml. Ten millilitres of Buffer P2 
(Lysis buffer) was added to the cell suspension, the solution mixed thoroughly 
and incubated at room temperature for no more than 5 minutes. Ten millilitres 
of chilled Buffer P3 (Neutralization buffer) was added to the lysate, mixed, 
applied to the Qiafilter cartridge and incubated at room temperature for 10 
minutes. After the 10 minutes incubation, the lysate was filtered into a sterile 
50 ml tube. Two and a half millilitres of endotoxin removal buffer (Buffer ER) 
was added to the filtrate, mixed and incubated on ice for 30 minutes. During 
the incubation a QIAGEN-tip 500 was equilibrated by applying the 10 ml of 
Buffer QBT (Equilibration buffer) to the columns and allowing the buffer to 
drain by gravity flow. After the incubation with endotoxin removal buffer the 
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solution was applied to the QIAGEN-tip and allowed to drain by gravity flow. 
The columns were washed twice with 30 ml of Buffer QC. The plasmids were 
eluted from the column with 15 ml Buffer QN (elution buffer). A 0.7x volume of 
isopropanol was used to precipitate the plasmids. The DNA was centrifuged at 
8000 rpm for 1 hour at 4°C. The DNA pellets were washed with endotoxin-free 
70% ethanol and re-centrifuged at 8000 rpm at 4°C for an additional hour. The 
pellets were air-dried and resuspended in an appropriate volume of endotoxin 
a free Tris-EDTA buffer.  
 
6.1.3 Gel Electrophoresis 
 
 
Regents 
 Tris Acetate EDTA Buffer (TAE) 
 Two hundred and forty two grams of Tris base was dissolved in 57.1 ml glacial  
acetic acid and 100 ml of 0.5 M EDTA (pH 8) .  
 
Ethidium Bromide 
One hundred milligrams of Ethidium Bromide was dissolved in 1 ml sterile 
water. Ethidium bromide solution was always covered with alumininium foil 
because it is light sensitive and stored at room temperature. 
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Protocol  
For 0.8% agarose gel, 0.8 g of molecular grade agarose was mixed with 100 
ml of 1x TAE and melted in a microwave for 2-4 minutes. The melted agarose 
was cooled at room temperature for 4 minutes before 5 µl of Ethidium Bromide 
solution was added. The mixture was then poured into a gel chamber and 
allowed to solidify. When it was ready to run, the gel was submerged in 1x TAE 
buffer in an electrophoresis chamber. The gels were run at 70 volts until the 
loading dye (Loading dye 6x, Fermentas, WI, USA) migrated to the edge of the 
gel. The DNA was visualized by placing the gel on an Ultraviolet (UV) 
Transilluminator.  
 
6.1.4 Transfection  
 
Reagents 
1000x Penicillin/Streptomycin 
Six hundred and ten milligrams of penicillin (100-000 U/ml, Invitrogen, Gibco-
BRL, CA, USA) and 1 g of Streptomycin (100 mg/ml, Invitrogen, Gibco-BRL, 
CA, USA) was dissolved in 10 ml of sterile water. The solution was sterilised 
by filtration through a 0.22 µm filter and stored at -20°C.  
Fetal calf serum (FCS) 
Fetal calf serum (FCS, Highveld Biological, South Africa) was heat inactivated 
before use at 60°C for 30 minutes.  
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0.5x Trypsin  
Five hundred microlitres of a 10x stock solution was made up to 50 ml and 
filter sterilised. 
RPMI medium 
RPMI medium was prepared as follows:10.4g of RPMI powder, 2g NaHCO3 , 
1.19 g HEPES, 1 ml Na2SeO3  stock (5.19 mg/L), 1 ml FeSO4.7H2O (27.8 
mg/L) 1 ml (NH4)6MO7O2 (3.71 mg/L), MnCl2.4H2O2 (0.059 mg/L), NH4VO3 
(1.17 mg/L) and 1m ethanolamine (1832.4 mg/L) were dissolved in Sabax 
water (Adcock Ingram, South Africa). The solution was filter sterilized by 
filtration through a 0.22 µm filter and stored at 4°C. 
Protocol  
Human hepatoma cells, Huh7, were maintained in RPMI supplemented with 
2.5% foetal calf serum, 1000x Penicillin/Streptomycin. On the day before 
transfection, 120 000 Huh7 cells were seeded in 1 ml per well of 4 cm2 without 
antibiotics. For preparation of transfection sample, plasmid DNA was diluted in 
100 µl Opti-MEM® I medium. Two microlitres of LipofectamineTM 2000 
(Invitrogen, CA, USA) was also diluted in 100 µl Opti-MEM® I medium. 
DNA:Opti-MEM and LipofectamineTM 2000:Opti-MEM mixtures were incubated 
at room temperature for approximately 5 minutes. After the 5 minutes 
incubation, diluted DNA and LipofectamineTM 2000 mixtures were combined, 
mixed gently, incubated for 20 minutes at room temperature. The 200 µl of 
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mixtures were added to each well containing Huh7 cells and growth medium. 
After transfection, complexes and cell medium were mixed by gentle agitation 
of the plate. Transfected cells were incubated for 48 hours at 37°C and 5% 
CO2 prior to testing for gene expression. Medium was changed after 4-6 hours, 
and fresh medium (medium containing penicillin/streptomycin antibiotic) was 
added to transfected cells. 
 
6.1.5 Dual-Luciferase® reporter Kit 
 
Reagents 
Preparation of Luciferase assay reagent II (LAR II) 
To prepare LAR II, lypophilised luciferase assay substrate was resuspended in 
10 ml of Luciferase assay buffer II, and mixed. LAR II solution (Promega, WI, 
USA) was always covered with aluminum foil because of its sensitivity to light 
and stored at -70 °C. 
Preparation of 1x Passive Lysis buffer (PLB).  
PLB is supplied as a 5x concentrate (Promega, WI, USA). To prepare a 1x 
working concentration, 1 volume of 5x PLB was mixed with 4 volumes of 
distilled water.   
Preparation of Stop & Glo® Reagent. 
Stop & Glo® Reagent is supplied at a 50x concentration (Promega, WI, USA). 
To prepare a working concentration, 1 volume of 50x Stop & Glo® substrate 
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was added to 50 volumes of Stop & Glo® Buffer in a 10 ml tube.  Stop & Glo® 
solution was stored at -70°C.  
Protocol 
Briefly, growth medium was removed and cells washed with saline. Required 
volume of 1x PLB was added and cells were homogenized on a shaker for 15 
minutes at room temperature. After the 15 minute incubation the lysates were 
aspirated and 20 µl of samples were transferred to a luminometer plate. To 
perform the Dual-Luciferase® reporter assay, the microplate was placed in the 
luminometer, followed by sequential auto-injection of the LAR II and Stop & 
Gluo® and initiate reading (Promega, WI, USA).  
 
6.1.6 RNA Extraction  
 
6.1.6.1 RNA extraction from cultured mammalian cells with Tri-reagent™ 
 
Regent 
Tri-reagent™ (Sigma, MO, USA) 
Monophase solution containing phenol and guanidine thiocyanate. This 
solution was stored at 4°C. 
Protocol 
The cells were lysed by repeated pipetting in 250 μl (per 12 well plate) of TRI 
reagent until a homogenous mixture was formed. The homogenate was 
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incubated at room temperature for 5 minutes, to promote complete dissociation 
of nucleoprotein complexes. Fifty microlitres of chloroform was added to the 
solution, vigorously mixed for 15 seconds and allowed to stand at room 
temperature for 2-5 minutes. After the incubation, the mixture was centrifuged 
for 15 minutes at 12 000xg at 4°C. Centrifugation separates the mixture into 3 
phases: red organic phase (containing protein), an interphase (containing 
DNA), and a colorless upper aqueous phase (containing RNA). The colorless 
upper aqueous phase was transferred to a new tube and the RNA was 
precipitated with 75 μl of isopropanol. The isopropanol mixture was stored at -
20°C until ready to be used.  After incubation, the mixture was centrifuged at 
12 000xg for 10 minute at 4°C. The RNA pellet was re-centrifuged in 70% 
ethanol at 12 000xg for 10 minutes at 4°C and supernatant was discarded. The 
pellet was air-dried and resuspended in an appropriate volume of DEPC-
treated water. 
 
6.1.6.2 Extraction of RNA from mouse liver with guanidium thiocyanate  
Reagents 
Guanidium solution  
Five hundred and ninety grams of guanidium thiocyanate was dissolved in 400 
ml DEPC-treated water.  Twenty five millilitres of 2 M Tris.HCl (pH 7.5) and 20 
ml of 0.5 M Na2EDTA (pH 8.0) were added to the solution and stirred overnight 
at 37oC.  After overnight incubation, the volume was adjusted to 950 ml with 
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sterile water and filtered. Fifty millilitres of 2-mercapto ethanol was added, and 
stored at room temperature for about three months. 
2 M Sodium acetate 
To prepare the sodium acetate solution, 16.42 g of sodium acetate was added 
to 40 ml sterile water and 35 ml of glacial acetic acid. The solution was 
adjusted to a pH of 4 with glacial acetic acid and the volume adjusted to 100 
ml. The solution was stored at room temperature. 
Water-saturated phenol  
To prepare water-saturated phenol, 100 g of phenol crystals were dissolved in 
water at 60°C. The upper water phase was aspirated and stored at 4°C.  
Diethylpyrocarbonate (DEPC) treated water 
DEPC-treated water was prepared as follows: 1 ml DEPC 
(diethylpyrocarbonate) was added per 1000 ml of sterile water. The DEPC 
solution was incubated at 37°C for 16 hours and the DEPC inactivated by 
autoclaving for 20 minutes at 121°C and 1 kg/cm2. DEPC treated water was 
stored at room temperature prior to use. 
 
RNA Extraction protocol 
The livers of the mice were harvested for total RNA preparation. One millilitre 
of guanidium solution (denaturation solution) was added to 100 mg of liver and 
tissue homogenised. The homogenised solution was transferred to a sterile 10 
ml tube. One hundred microlitres of 2 M sodium acetate (pH 4) was added and 
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mixed thoroughly by inversion.  One millilitre of water-saturated phenol was 
added to the solution, mixed thoroughly and 0.2 ml of 49:1 chloroform/isoamyl 
alcohol added. The solution was mixed and then incubated for 15 minutes at 
4°C. The upper aqueous phase was removed, 1 ml of 100% isopropanol 
added, mixed and incubated at -20°C for about 16 hours. After incubation, the 
samples were centrifuged for 30 minutes at 10 000 g at 4°C. After 
centrifugation the supernatant was discarded. The RNA pellet was washed 
with 70% DEPC-ethanol, vortexed, and incubated for 15 minutes at room 
temperature,  re-centrifuged at 10 000 g for 5 minutes at 4°C and supernatant 
was discarded. The pellet was air-dried and resuspended in an appropriate 
volume of DEPC-treated water. 
 
6.1.7 Immunohistochemical staining 
 
Reagent  
HBcAg Antibody swell (Signet Cat) 
Tris-buffered saline (TBS) 
To prepare TBS buffer (1x), 6.05 g Tris and 8.7 g NaCl were dissolved in 800  
ml of water. The solution was adjusted to a pH of 7.5 with 1 M HCl and the 
volume adjusted to 1 litre. The solution was stored at 4°C. 
TBS with 0.05% Tween 20   (TTBS buffer).   
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Protocols 
Livers were fixed in 20% paraformaldyhyde, processed, embedded in 
parafinwax 5 micro sections were mounted on Poly-L-Lysine coated slides. 
These were dewaxed, hydrated and rinsed in 0.05% Tween 20 in TBS (TTBS 
buffer). Using an Envision Kit (Dako Cat number K5007), sections underwent 
endogenous enzyme blocking for 30 minutes. The sections were rinsed again 
in TTBS buffer and then incubated with primary HBV core antibody, diluted 
1:10 with diluting buffer for 45 minutes at room temperature. After washing with 
TTBS buffer the sections were labeled with secondary labeled polymer HRP 
and incubated for 30 minutes at room temperature.  After the 30 minutes 
incubation, the sections were rinsed in TTBS buffer and washed in fresh 
solution for 5 minutes. After being washed, the sections were developed by 
substrate solution of Chromogen (2 drops of Diaminobenzidine in 2ml buffer) 
and incubated 10 minutes at room temperature. Thereafter liver sections were 
washed in distilled water, stained with Haematoxylin for 3 minutes. Liver 
sections were dehydrated, cleared and mounted. The HBcAg was observed as 
brown coloration under microscopy.  
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